Consolidation immunotherapy shows early promise in limited-stage SCLC

Design

Phase 2, randomised controlled trial, stopped early (GASTO-1052A)

Population

98 patients with limited-stage SCLC after chemoradiotherapy

Primary outcome

Progression-free survival

Effect

PFS hazard ratio 0.55 (0.31–0.96); OS hazard ratio 0.39 (0.19–0.80)

Immunotherapy transformed extensive-stage small-cell lung cancer, but limited-stage disease has lacked it. GASTO-1052A, a phase 2 trial, randomised 98 patients who had completed chemoradiotherapy for limited-stage SCLC to six months of consolidation toripalimab or observation.

The trial was stopped early. Median progression-free survival was not reached with toripalimab versus 14.1 months with observation (hazard ratio 0.55), and overall survival was not reached versus 30.3 months (hazard ratio 0.39), with benefit consistent across subgroups. Toxicity was generally mild, though 12.5% stopped the drug for adverse events and grade 3 pneumonitis occurred in 4.2%.

This points the same way as the larger ADRIATIC programme: consolidation immunotherapy after chemoradiotherapy may extend survival in limited-stage SCLC. But with only 98 patients and early termination, the effect size is uncertain and the finding needs a larger, adequately powered trial before it becomes standard — the signal is encouraging, the evidence not yet definitive.

• Consolidation toripalimab after chemoradiotherapy improved progression-free and overall survival in limited-stage SCLC.
• Progression-free and overall survival were not reached in the toripalimab arm.
• Toxicity was mostly mild, with grade 3 pneumonitis in about 4%.
• The trial was small and stopped early, so the effect size is uncertain.

Why it matters

It extends the consolidation-immunotherapy strategy from extensive- to limited-stage SCLC, where options have been few.

Don't overread it

98 patients and early termination tend to overstate benefit; these are promising signals, not a basis to change standard care yet.

The statistics, in plain English

Hazard ratios of 0.55 and 0.39 look striking, but with a median not yet reached in a small, early-stopped trial the confidence intervals are wide and the true benefit less certain than the numbers suggest.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.